Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CALYPSO phase 3 study of eneboparatide in chronic hypoparathyroidism
2022-503126-12-01Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- Jan 2024
- Modality
- Small Molecules, Peptides
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in chronic hypoparathyroidism comparing Eneboparatide with Placebo (2 arms). Primary endpoint: Composite efficacy response at Week 24. Planned start Jan 2024; status: authorised.
02
Drugs
eneboparatide
03
Conditions
chronic hypoparathyroidism
Beyond the preview
Go deeper on 2022-503126-12-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503126-12-01.